Agerafenib
Agerafenib (CEP32496) is a potent and selective BRAF kinase inhibitor. It is used in biochemical and cellular research to study oncogenic BRAF signaling and has demonstrated activity in preclinical in vitro and in vivo models of BRAF-mutant cancers.
Product Specifications
CAS Number
1188910-76-0
Product Name Alternative
CRET, CEP32496, CEP-32496, CEP 32496, c-Kit, cKit, Abl1, Agerafenib, BcrAbl, Lck, Inhibitor, inhibit, PDGFRβ, RXDX 105, RXDX105, RXDX-105, RET, Raf, Raf kinases
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
95.78% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.87 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:45 mg/mL (86.96 mM)
Smiles
COc1cc2ncnc (Oc3cccc (NC (=O) Nc4cc (on4) C (C) (C) C (F) (F) F) c3) c2cc1OC
Molecular Formula
C24H22F3N5O5
Molecular Weight
517.46
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
